Nigel H. Russell

Assessment of Minimal Residual Disease in Standard-Risk AML

Adam Ivey, Robert K. Hills, Michael A. Simpson et al. · New England Journal of Medicine · 2016 · 812 citations · Full text

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Alan K. Burnett, Robert K. Hills, Donald Milligan et al. · Journal of Clinical Oncology · 2010 · 644 citations · Full text

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

Brian A. Walker, Eileen M. Boyle, Christopher P. Wardell et al. · Journal of Clinical Oncology · 2015 · 557 citations · Full text

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial

Alan K. Burnett, Nigel H. Russell, Robert K. Hills et al. · The Lancet Oncology · 2015 · 533 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +8

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Jörge E. Cortes, Samer K. Khaled, Giovanni Martinelli et al. · The Lancet Oncology · 2019 · 465 citations

Hematological Malignancy, Medicine, Hematology +5